New York-based AI biotech company Envisagenics has raised an undisclosed amount in a Series B funding round, which saw participation from existing investors Third Kind Venture Capital, Empire State Development, and Red Cell Partners, along with new investor Bristol Myers Squibb.
The firm intends to use the raised capital to expand and enhance its preclinical oncology assets with its proprietary AI drug discovery platform SpliceCore.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.